FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2761851330> ?p ?o ?g. }

• W2761851330 endingPage "v79" @default.
• W2761851330 startingPage "v79" @default.
• W2761851330 abstract "Background: Overall response rates of 13-19% have been reported with checkpoint inhibitor monotherapy in chemotherapy-resistant, PD-L1-positive mTNBC. RT is frequently used to enhance local control in mTNBC and has been reported to induce distant (abscopal) tumor responses when combined with immunotherapy. In this study we evaluate the safety and efficacy of RT combined with the anti-PD-1 inhibitor, pembro, in a single-arm, two-stage, phase II study in mTNBC (NCT02730130). Methods: Eligible women had biopsy-proven mTNBC, ECOG performance status 0-2, and ≥2 measurable sites of metastatic disease with at least 1 site requiring RT. A total RT dose of 3000 cGy was delivered in 5 daily fractions. IV pembro was given at 200mg within 3 days of first RT fraction then every 3 weeks until disease progression. The primary endpoint was overall response rate at week 13 in the non-irradiated lesions by RECIST v1.1. Secondary endpoints included safety and overall survival. Tumor biopsies were obtained at baseline and at week 7. PD-L1 expression was not required for study entry. Results: As of May 1, 2017, the study has completed enrollment (N = 17) with 4 women on treatment pending 13-week evaluation. Median age was 52y (range 37-73y). Median number of prior therapies received for metastatic disease was 3 (range 0 to 8). Of the 7 women not evaluable at 13 weeks: 5 died secondary to disease-related complications (at weeks 2, 6, 7, 8, and 9) and 2 came off study due to disease progression prior to week 13. Of the 6 women evaluable at week 13, 2 (33%) had a partial response (PR), 1 (17%) had stable disease (SD) and 3 (50%) had disease progression. The 2 PRs represented 76% and 75% decreases in tumor burden by RECIST v1.1 durable for 21 and 31 weeks, respectively. SD response was durable for 30 weeks. Common toxicities were mild and included fatigue, myalgia and nausea. Conclusions: The combination of pembro and RT was well-tolerated. This is a poor prognosis population with 5/13 (38%) evaluable patients dying within 12 weeks of study entry. However, durable responses were observed outside of the RT field in 2/6 (33%) patients who were unselected for PD-L1 expression and evaluable at 13 weeks. Safety and toxicity data for all study patients will be presented. Clinical trial identification: NCT02730130 Legal entity responsible for the study: Memorial Sloan Kettering Cancer Center Funding: Merck Disclosure: H.L. McArthur: Advisory boards for Celgene, Merck, OBI Pharma, Spectrum, Syndax, Roche, Peregrine, Calithera, Eli Lilly, and TapImmune. Research supported by Bristol-Myers Squibb; Eli Lilly; MedImmune, LLC/AstraZeneca; and Merck. C.A. Barker: In the past year has received research funding from Elekta, Merck, and Amgen; honoraria from Driver Group, a biotechnology company; and served as a Pfizer advisory board consultant. A. Gucalp: Research funding from Pfizer and Innocrin related to other work in triple negative breast cancer. A. Ho: Research funding by Merck. All other authors have declared no conflicts of interest." @default.
• W2761851330 created "2017-10-20" @default.
• W2761851330 creator A5000512963 @default.
• W2761851330 creator A5007002927 @default.
• W2761851330 creator A5018503091 @default.
• W2761851330 creator A5019002150 @default.
• W2761851330 creator A5031423623 @default.
• W2761851330 creator A5032667690 @default.
• W2761851330 creator A5051075802 @default.
• W2761851330 creator A5058653439 @default.
• W2761851330 creator A5068650146 @default.
• W2761851330 creator A5074677674 @default.
• W2761851330 creator A5090679372 @default.
• W2761851330 date "2017-09-01" @default.
• W2761851330 modified "2023-09-27" @default.
• W2761851330 title "A single-arm, phase ii study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC)" @default.
• W2761851330 doi "https://doi.org/10.1093/annonc/mdx365.010" @default.
• W2761851330 hasPublicationYear "2017" @default.
• W2761851330 type Work @default.
• W2761851330 sameAs 2761851330 @default.
• W2761851330 citedByCount "9" @default.
• W2761851330 countsByYear W27618513302017 @default.
• W2761851330 countsByYear W27618513302018 @default.
• W2761851330 countsByYear W27618513302019 @default.
• W2761851330 countsByYear W27618513302020 @default.
• W2761851330 countsByYear W27618513302022 @default.
• W2761851330 countsByYear W27618513302023 @default.
• W2761851330 crossrefType "journal-article" @default.
• W2761851330 hasAuthorship W2761851330A5000512963 @default.
• W2761851330 hasAuthorship W2761851330A5007002927 @default.
• W2761851330 hasAuthorship W2761851330A5018503091 @default.
• W2761851330 hasAuthorship W2761851330A5019002150 @default.
• W2761851330 hasAuthorship W2761851330A5031423623 @default.
• W2761851330 hasAuthorship W2761851330A5032667690 @default.
• W2761851330 hasAuthorship W2761851330A5051075802 @default.
• W2761851330 hasAuthorship W2761851330A5058653439 @default.
• W2761851330 hasAuthorship W2761851330A5068650146 @default.
• W2761851330 hasAuthorship W2761851330A5074677674 @default.
• W2761851330 hasAuthorship W2761851330A5090679372 @default.
• W2761851330 hasBestOaLocation W27618513301 @default.
• W2761851330 hasConcept C121608353 @default.
• W2761851330 hasConcept C126322002 @default.
• W2761851330 hasConcept C143998085 @default.
• W2761851330 hasConcept C203092338 @default.
• W2761851330 hasConcept C2775930923 @default.
• W2761851330 hasConcept C2776694085 @default.
• W2761851330 hasConcept C2777701055 @default.
• W2761851330 hasConcept C2779984678 @default.
• W2761851330 hasConcept C2780057760 @default.
• W2761851330 hasConcept C2780110267 @default.
• W2761851330 hasConcept C31760486 @default.
• W2761851330 hasConcept C509974204 @default.
• W2761851330 hasConcept C530470458 @default.
• W2761851330 hasConcept C535046627 @default.
• W2761851330 hasConcept C71924100 @default.
• W2761851330 hasConceptScore W2761851330C121608353 @default.
• W2761851330 hasConceptScore W2761851330C126322002 @default.
• W2761851330 hasConceptScore W2761851330C143998085 @default.
• W2761851330 hasConceptScore W2761851330C203092338 @default.
• W2761851330 hasConceptScore W2761851330C2775930923 @default.
• W2761851330 hasConceptScore W2761851330C2776694085 @default.
• W2761851330 hasConceptScore W2761851330C2777701055 @default.
• W2761851330 hasConceptScore W2761851330C2779984678 @default.
• W2761851330 hasConceptScore W2761851330C2780057760 @default.
• W2761851330 hasConceptScore W2761851330C2780110267 @default.
• W2761851330 hasConceptScore W2761851330C31760486 @default.
• W2761851330 hasConceptScore W2761851330C509974204 @default.
• W2761851330 hasConceptScore W2761851330C530470458 @default.
• W2761851330 hasConceptScore W2761851330C535046627 @default.
• W2761851330 hasConceptScore W2761851330C71924100 @default.
• W2761851330 hasLocation W27618513301 @default.
• W2761851330 hasOpenAccess W2761851330 @default.
• W2761851330 hasPrimaryLocation W27618513301 @default.
• W2761851330 hasRelatedWork W2034849620 @default.
• W2761851330 hasRelatedWork W2418436192 @default.
• W2761851330 hasRelatedWork W2534174115 @default.
• W2761851330 hasRelatedWork W2982645126 @default.
• W2761851330 hasRelatedWork W3010740851 @default.
• W2761851330 hasRelatedWork W3164806321 @default.
• W2761851330 hasRelatedWork W3177224496 @default.
• W2761851330 hasRelatedWork W4221049467 @default.
• W2761851330 hasRelatedWork W4322775203 @default.
• W2761851330 hasRelatedWork W4379285952 @default.
• W2761851330 hasVolume "28" @default.
• W2761851330 isParatext "false" @default.
• W2761851330 isRetracted "false" @default.
• W2761851330 magId "2761851330" @default.
• W2761851330 workType "article" @default.